Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Breast Cancer Research Center, Motamed Cancer Institute, ACERCR, Tehran, Iran.
J Cancer Res Clin Oncol. 2023 Aug;149(9):6115-6129. doi: 10.1007/s00432-023-04583-8. Epub 2023 Jan 19.
MicroRNAs (miRNAs) are regulatory molecules capable of positively or negatively regulating signaling pathways, and are involved in tumorigenesis as well as various aspects of cancer. The purpose of this study was to investigate the expression levels of miR-133a, miR-637, and miR-944 in serum and tumor tissues as well as their relationship with the expression level of phosphatidylinositol-3-kinase (PI3K) and protein kinase-B (AKT) genes and proteins along with their clinical significance in breast cancer.
The expressions of miR-133a, miR-637, miR-944, PI3K, and AKT genes were examined in the tumor and tumor margin tissues of 40 patients with breast cancer, as well as the serum levels of miR-133a, miR-637, and miR-944 in these patients and 40 healthy groups by quantitative real-time PCR (qRT-PCR). PI3K and AKT proteins expression in tumor and tumor margin tissues were detected using immunohistochemistry (IHC).
The expression levels of miR-133a and miR-637 in the tumor tissue and serum of patients were lower than those in the tumor margin tissue and serum of the healthy group, respectively. In addition, the expression level of miR-944 in the tumor tissue was lower than that in the tumor margin tissue, but its expression increased in the serum of cancer patients compared to that in the healthy group. The expression of miR-637 was correlated with tumor location and Her2 receptors, and the expression of miR-944 was correlated with tumor location and family history. PI3K and AKT mRNA and protein levels were higher in the tumor tissues than in the tumor margin tissues (p < 0.05).
The results of our study revealed that miR-637 has a better diagnostic value in breast cancer than miR-133a and miR-944.
微小 RNA(miRNA)是一种能够正向或负向调控信号通路的调节分子,参与肿瘤的发生以及癌症的各个方面。本研究旨在探讨血清和肿瘤组织中 miR-133a、miR-637 和 miR-944 的表达水平及其与磷酸肌醇-3-激酶(PI3K)和蛋白激酶-B(AKT)基因及蛋白表达的关系及其在乳腺癌中的临床意义。
采用实时定量 PCR(qRT-PCR)检测 40 例乳腺癌患者肿瘤及肿瘤边缘组织中 miR-133a、miR-637、miR-944、PI3K 和 AKT 基因的表达,采用 qRT-PCR 检测 40 例健康组患者和患者血清中 miR-133a、miR-637 和 miR-944 的表达。采用免疫组织化学(IHC)检测肿瘤及肿瘤边缘组织中 PI3K 和 AKT 蛋白的表达。
miR-133a 和 miR-637 在肿瘤组织和患者血清中的表达水平低于肿瘤边缘组织和健康组血清中的表达水平。miR-944 在肿瘤组织中的表达水平低于肿瘤边缘组织,但其在癌症患者血清中的表达水平高于健康组。miR-637 的表达与肿瘤位置和 Her2 受体有关,miR-944 的表达与肿瘤位置和家族史有关。PI3K 和 AKTmRNA 和蛋白水平在肿瘤组织中高于肿瘤边缘组织(p<0.05)。
本研究结果表明,miR-637 在乳腺癌中的诊断价值优于 miR-133a 和 miR-944。